[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Synnovation Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100650976","first-in-human-study-of-snv1521-with-a-ras-inhibitor-for-people-with-advanced-pancreatic-cancer-100650976",false,"NCT07756281","First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer","A Phase 1, Open-Label, Dose-Escalation and Expansion Study of SNV1521 in Combination With RAS Inhibition in Participants With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","Inclusion Criteria:\n\n* Adults (18 years and older).\n* Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.\n* Cancer confirmed by tissue or cell examination (histology or cytology).\n* At least one measurable tumor on scans.\n* Good enough general health and organ function to receive study treatment, as judged by the study doctor.\n* Able to swallow oral medicines.\n* Willing to follow study visit schedule and contraception requirements.\n\nExclusion Criteria:\n\n* Serious heart, lung, liver, or other medical problems that would make study treatment unsafe.\n* Active, uncontrolled infections.\n* Other active cancers that could interfere with study assessments (except certain early-stage cancers that have been treated).\n* Prior treatments or medicines that are not allowed by the protocol (for example, some strong drug interactions).\n* Known brain or nervous system involvement from the cancer that is not stable or controlled.\n* Pregnant or breastfeeding, or unwilling to use required birth control during and after the study.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.",[26,27],"Pancreatic Cancer","Pancreatic Acinar Carcinoma",[29,30,31,32],"daraxonrasib","PARP","pancreas","pancreatic cancer","NOT_YET_RECRUITING","2026-08-05",{"date":36,"type":37},"2026-08-10","ACTUAL",{"date":39,"type":20},"2026-09",{"date":41,"type":20},"2029-06-01",{"name":43,"class":44},"Synnovation Therapeutics, Inc.","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100533057","phase-1-snv1521-in-participants-with-advanced-solid-tumors-100533057","NCT06220864","SNV1521 in Participants With Advanced Solid Tumors","A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Advanced or metastatic solid tumor malignancy\n* Evaluable or Measurable disease (RECIST 1.1 Criteria).\n* ECOG Performance Status 0 or 1.\n* Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* History of other malignancy within the past 2 years\n* Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia\n* Significant cardiovascular disease within 6 months\n* Significant gastrointestinal disease\n* HIV infection with a CD4+ T-cell count \\\u003C 200 cells\u002FμL and\u002For a detectable viral load\n* Liver dysfunction",{"count":53,"type":20},400,[23],"This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.",[57],"Advanced Solid Tumor","RECRUITING","2026-06-23",{"date":61,"type":37},"2026-06-25",{"date":63,"type":37},"2024-02-23",{"date":65,"type":20},"2027-12",{"name":43,"class":44},25,""]